Fox Chase Cancer Center News

PHILADELPHIA (October 12, 2020)—Researchers at Fox Chase Cancer Center recently published a case study that proposes that severe low calcium levels known as hypocalcemia may result from an inflammatory reaction with transient hypoparathyroidism after hyperthermic intraperitoneal chemotherapy (HIPEC) treatment.

PHILADELHIA (October 12, 2020) — Colleen Tetzlaff, MHS, PA-C, an advanced practice clinician at Fox Chase Cancer Center, was recently named president of the Association of Physician Assistants in Oncology (APAO) for 2020-2021.

PHILADELPHIA (October 9, 2020)—October is Breast Cancer Awareness Month, and Fox Chase Cancer Center encourages women to schedule a screening mammogram for breast cancer. Screening mammograms can help detect breast cancer early, before any symptoms appear, and when there is better chance for successful treatment.

PHILADELPHIA (October 7, 2020)— Joan Font-Burgada, PhD, assistant professor in the Cancer Biology Research Program at Fox Chase Cancer Center, has received a National Institutes of Health (NIH) Director’s New Innovator Award from the NIH Common Fund’s High-Risk, High-Reward Research program.

PHILADELPHIA (October 6, 2020)—Press Ganey has recognized Fox Chase Cancer Center with its 2020 Guardian of Excellence Award for providing outstanding clinical performance for patients in its outpatient clinics.

PHILADELPHIA (October 6, 2020) – Researchers at Fox Chase Cancer Center have discovered a new function for the histone lysine demethylase KDM4A that supports its role as a “critical regulator” for replicative histones during the S phase of the cell cycle.

PHILADELPHIA (October 6, 2020)—In a recent study, researchers at Fox Chase Cancer Center found individuals with lower health literacy or income reported more practical issues and problems with coping following localized prostate cancer treatment.

PHILADELPHIA (October 1, 2020) – Active surveillance is being increasingly used as a treatment option for men diagnosed with low-risk prostate cancer. A recent study led by researchers at Fox Chase Cancer Center, however, has found that only about 60% of men who choose active surveillance are undergoing guideline-recommended confirmatory biopsy within 12 months of their diagnosis.